The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued for luspate...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000616 |
| _version_ | 1797285204212056064 |
|---|---|
| author | Julio Delgado Caroline Voltz Milena Stain Ewa Balkowiec-Iskra Brigitte Mueller Johanna Wernsperger Iwona Malinowska Christian Gisselbrecht Harald Enzmann Francesco Pignatti |
| author_facet | Julio Delgado Caroline Voltz Milena Stain Ewa Balkowiec-Iskra Brigitte Mueller Johanna Wernsperger Iwona Malinowska Christian Gisselbrecht Harald Enzmann Francesco Pignatti |
| author_sort | Julio Delgado |
| collection | DOAJ |
| description | Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued for luspatercept for the treatment of adult patients with transfusion-dependent anemia caused by very low-, low-, and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, or those with transfusion-dependent beta thalassemia (BT). Luspatercept was evaluated in 2 separate phase 3, double-blind, placebo-controlled multicentre trials. The primary endpoints of these trials were the percentage of patients achieving transfusion independence over ≥8 weeks or longer for patients with MDS, and the percentage of patients achieving a ≥33% reduction in transfusion burden from baseline to week 13–24 for patients with BT. In the MDS trial, the percentage of responders was 37.91% versus 13.16%, P < 0.0001, for patients receiving luspatercept versus placebo, respectively. In the BT trial, the percentage of responders was 21.4% versus 4.5% (P < 0.0001) for luspatercept versus placebo, respectively. Treatment with luspatercept led to similar incidences of adverse events (AEs), but higher incidences of grade ≥3 AEs and serious AEs compared to placebo. The most frequently reported treatment-emergent AEs (≥15%) in the pooled luspatercept group were headache; back pain, bone pain, and arthralgia; diarrhea; fatigue; pyrexia; and cough. The aim of this article is to summarize the scientific review of the application, which led to the regulatory approval in the EU. |
| first_indexed | 2024-03-07T17:59:53Z |
| format | Article |
| id | doaj.art-a3006b67091a4eebbe6f6aaeeadc8c60 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:59:53Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-a3006b67091a4eebbe6f6aaeeadc8c602024-03-02T11:11:41ZengWileyHemaSphere2572-92412021-08-0158e61610.1097/HS9.0000000000000616202108000-00011The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemiaJulio Delgado0Caroline Voltz1Milena Stain2Ewa Balkowiec-Iskra3Brigitte Mueller4Johanna Wernsperger5Iwona Malinowska6Christian Gisselbrecht7Harald Enzmann8Francesco Pignatti91 Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands1 Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands3 Bundesamt fur Sicherheit im Gesundheitswesen, Vienna, Austria4 Committe for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands3 Bundesamt fur Sicherheit im Gesundheitswesen, Vienna, Austria3 Bundesamt fur Sicherheit im Gesundheitswesen, Vienna, Austria5 Urząd Rejestracji Produktów Leczniczych, Wyrobow Medycznych i Produktów Biobójczych, Warsaw, Poland8 Department of Haematology, Hopital Saint Louis, Paris, France4 Committe for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands1 Oncology and Haematology Office, European Medicines Agency, Amsterdam, The NetherlandsLuspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued for luspatercept for the treatment of adult patients with transfusion-dependent anemia caused by very low-, low-, and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, or those with transfusion-dependent beta thalassemia (BT). Luspatercept was evaluated in 2 separate phase 3, double-blind, placebo-controlled multicentre trials. The primary endpoints of these trials were the percentage of patients achieving transfusion independence over ≥8 weeks or longer for patients with MDS, and the percentage of patients achieving a ≥33% reduction in transfusion burden from baseline to week 13–24 for patients with BT. In the MDS trial, the percentage of responders was 37.91% versus 13.16%, P < 0.0001, for patients receiving luspatercept versus placebo, respectively. In the BT trial, the percentage of responders was 21.4% versus 4.5% (P < 0.0001) for luspatercept versus placebo, respectively. Treatment with luspatercept led to similar incidences of adverse events (AEs), but higher incidences of grade ≥3 AEs and serious AEs compared to placebo. The most frequently reported treatment-emergent AEs (≥15%) in the pooled luspatercept group were headache; back pain, bone pain, and arthralgia; diarrhea; fatigue; pyrexia; and cough. The aim of this article is to summarize the scientific review of the application, which led to the regulatory approval in the EU.http://journals.lww.com/10.1097/HS9.0000000000000616 |
| spellingShingle | Julio Delgado Caroline Voltz Milena Stain Ewa Balkowiec-Iskra Brigitte Mueller Johanna Wernsperger Iwona Malinowska Christian Gisselbrecht Harald Enzmann Francesco Pignatti The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia HemaSphere |
| title | The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia |
| title_full | The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia |
| title_fullStr | The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia |
| title_full_unstemmed | The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia |
| title_short | The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia |
| title_sort | european medicines agency review of luspatercept for the treatment of adult patients with transfusion dependent anemia caused by low risk myelodysplastic syndromes with ring sideroblasts or beta thalassemia |
| url | http://journals.lww.com/10.1097/HS9.0000000000000616 |
| work_keys_str_mv | AT juliodelgado theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT carolinevoltz theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT milenastain theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT ewabalkowieciskra theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT brigittemueller theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT johannawernsperger theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT iwonamalinowska theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT christiangisselbrecht theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT haraldenzmann theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT francescopignatti theeuropeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT juliodelgado europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT carolinevoltz europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT milenastain europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT ewabalkowieciskra europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT brigittemueller europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT johannawernsperger europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT iwonamalinowska europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT christiangisselbrecht europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT haraldenzmann europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia AT francescopignatti europeanmedicinesagencyreviewofluspaterceptforthetreatmentofadultpatientswithtransfusiondependentanemiacausedbylowriskmyelodysplasticsyndromeswithringsideroblastsorbetathalassemia |